The Preliminary Results of Bortezomib Used as A Primary Treatment for An Early Acute Antibody-Mediated Rejection after Kidney Transplantation—A Single-Center Case Series

The Preliminary Results of Bortezomib Used as A Primary Treatment for An Early Acute Antibody-Mediated Rejection after Kidney Transplantation—A Single-Center Case Series

Proteasome inhibitor bortezomib has been used in the treatment of refractory cases of acute and chronic antibody-mediated rejection (AMR) in kidney transplant recipients. However, its efficacy and safety as a primary treatment for early AMR has been scarcely investigated. We herein present our preli...

Full description

Bibliographic Details
Main Authors: Aureliusz Kolonko, Natalia Słabiak-Błaż, Henryk Karkoszka, Andrzej Więcek, Grzegorz Piecha
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Journal of Clinical Medicine
Subjects:
acute humoral rejection
first-line therapy
outcomes
proteasome inhibitor
Online Access:https://www.mdpi.com/2077-0383/9/2/529

Internet

https://www.mdpi.com/2077-0383/9/2/529

Similar Items